Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pedigree Analysis01:35

Pedigree Analysis

Overview
Genetic Lingo01:11

Genetic Lingo

Overview
Incomplete Dominance01:43

Incomplete Dominance

Gregor Mendel's work (1822 - 1884) was primarily focused on pea plants. Through his initial experiments, he determined that every gene in a diploid cell has two variants called alleles inherited from each parent. He suggested that amongst these two alleles, one allele is dominant in character and the other recessive. The combination of alleles determines the phenotype of a gene in an organism.
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Temporal Artery Mapping With Microvascular Imaging: Anatomical Considerations for Filler Injections.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·2026
Same author

Efficiency of KTP laser for verrucae vulgaris and plantaris: A retrospective analysis.

Journal of cosmetic dermatology·2023
Same author

Evaluation of supratrochlear artery depth and course variations by Doppler ultrasonography along the glabellar frown lines for safer filler injections.

Journal of cosmetic dermatology·2022
Same author

The place of B-mode ultrasonography, shear-wave elastography, and superb microvascular imaging in the pre-diagnosis of androgenetic alopecia.

Journal of cosmetic dermatology·2021
Same author

Pregnancy-associated granulomatous mastitis of accessory breast: A novel clinical presentation.

Dermatologic therapy·2020
Same author

Glomerular hair sign: New trichoscopic finding in a patient with trichothiodystrophy.

Dermatologic therapy·2020

Related Experiment Video

Updated: May 28, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Genetics of Behçet's Disease.

Tamer İrfan Kaya1

  • 1Department of Dermatology, Faculty of Medicine, Mersin University, 33079 Mersin, Turkey.

Pathology Research International
|October 21, 2011
PubMed
Summary

Genetic factors significantly influence Behçet's disease (BD) susceptibility. The Human Leukocyte Antigen B51 (HLA-B51) is a key genetic marker, with other genetic associations also playing a role in disease development.

Area of Science:

  • Immunogenetics
  • Rheumatology
  • Systemic Inflammatory Disorders

Background:

  • Behçet's disease (BD) is a systemic inflammatory condition marked by recurrent oral/genital ulcers and ocular inflammation.
  • Genetic predisposition is recognized as a significant factor in BD susceptibility, evidenced by its unique geographical distribution and familial aggregation.
  • The Human Leukocyte Antigen B51 (HLA-B51) subtype is the most established genetic marker for BD, particularly in Silk Road regions.

Purpose of the Study:

  • To review and synthesize findings from Human Leukocyte Antigen (HLA) and non-HLA genetic association studies in Behçet's disease.
  • To highlight the role of genetic factors in BD susceptibility and severity.

Main Methods:

  • Review of existing genome-wide association studies (GWAS) and genetic polymorphism studies.

More Related Videos

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

Related Experiment Videos

Last Updated: May 28, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

  • Analysis of established genetic markers, including HLA-B51.
  • Examination of geographical distribution and familial aggregation patterns.

    • Main Results:

    • HLA-B51 (specifically the B510101 subtype) is strongly associated with BD in populations along the Silk Road.
    • Recent GWAS and polymorphism studies have identified additional genetic associations contributing to BD susceptibility and/or severity.
    • Genetic factors are confirmed as a major determinant in the etiology of Behçet's disease.

    Conclusions:

    • Genetic predisposition, particularly HLA-B51, plays a crucial role in Behçet's disease.
    • Non-HLA genetic factors likely contribute to the complex genetic architecture of BD.
    • Further research into genetic associations can elucidate BD pathogenesis and inform potential therapeutic strategies.